Mercer Global Advisors
HTGM

Mercer Global Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Mercer Global Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-195
Closed -$11K – 1203
2020
Q1 		$11K Buy
+195
New +$19.1K ﹤0.01% 1091

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KM
Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mercer Global Advisors's HTGM Position: Q2 2020 in Review

Mercer Global Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 195 shares — an estimated $11K sold.

Mercer Global Advisors first reported a position in HTGM in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

  • Mercer Global Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Mercer Global Advisors sold 195 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $11K.
  • Mercer Global Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Mercer Global Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $11K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on Mercer Global Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.